

Company Fact Sheet

Headquarters:

25841 Industrial Blvd. Suite 275
Hayward, CA 94545
USA
+1 650.239.9070

Number of Employees:

190+

RefleXion Medical:

A privately held biotargeting oncology company founded in 2009 by Sam Mazin, Ph.D. and Akshay Nanduri to create a new radiation treatment modality through biological guidance for the treatment of localized and metastatic cancer.

RefleXion Technology:

RefleXion is developing a biology-guided radiotherapy (BgRT)* machine that is the first to utilize the cancer's biology itself to guide radiation delivery, even in tumors that are moving. The technology uses positron emission tomography (PET) to guide personalized radiotherapy. RefleXion's platform enables a leap forward in the ongoing goal of conventional radiotherapy to manage motion, and potentially diminish radiation toxicity, making it feasible to one day treat multiple tumors in parallel during the same session.

Currently, the RefleXion machine is cleared by the U.S. Food and Drug Administration (FDA) for the delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT).

PET and Radiotherapy:

RefleXion's technology combines PET imaging with stereotactic radiotherapy for localization and real-time tracking at the time of treatment delivery. By using the tumor's own emissions to guide radiation delivery, treatment margins and the radiation dose to healthy tissue may be significantly reduced. This approach represents a significant advance for patients by leveraging a proven modality for visualizing cancer with one of the most effective ways to treat cancer.

Funding & Investors:

RefleXion raised over \$160M in its Series C round of funding and most recently secured a \$60M credit facility with Oxford Capital. The company is backed by premier investment firms TPG Growth/The Rise Fund, China-focused healthcare investment firm GT Healthcare Capital Partners, KCK Group, Sofinnova Partners, T. Rowe Price, Venrock, Pfizer Venture Investments, and Johnson & Johnson Innovation – JJDC, Inc. The company also received grant funding from the National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Program.

Media Resources:

Todd Powell, president, CEO
Sam Mazin, Ph.D., founder, CTO
Martyn Webster, CFO
Thorsten Melcher, CBO
Sean Shirvani, M.D., senior vp, medical affairs
Judy Bartlett-Roberto, vp, marketing

Media Contact:

Amy Cook
acook@reflexion.com

Investor Contact:

Martyn Webster
martyn@reflexion.com

The Reflexion™ X1 BgRT capability requires 510(k) clearance and is not available for sale.